MindImmune Therapeutics just made the kind of move that turns a quiet biotech into a conversation starter. The company closed a 10.2M Series A extension led by Dolby Family Ventures, pushing total Series A funding to a clean 30M. They paired the announcement with the arrival of Isaac Stoner as CEO, which is the corporate version of dropping a needle on a record right as the room leans in. Timing like that is not luck. It is a team that knows exactly where it stands in the neurodegeneration landscape and is not afraid to show its hand.
The founders Stevin H. Zorn PhD, Frank S. Menniti PhD, Robert B. Nelson PhD, and Brian M. Campbell PhD have been committed to the long game since 2016, when they built MindImmune Therapeutics out of the insight that Alzheimers might have less to do with the usual suspects and more to do with immune cells slipping into the brain from the bloodstream. These four spent years inside Pfizer and Lundbeck studying CNS disorders long before neuroinflammation became the trendy term it is today. They saw the pattern forming before everyone else caught the beat.
What makes this chapter even more interesting is the company’s dual-state evolution. MindImmune Therapeutics planted its scientific roots in Rhode Island through a collaboration with the University of Rhode Island’s Ryan Institute for Neuroscience, gaining lab infrastructure, academic firepower, and a community that backs bold science. Now the recent funding release datelined Cambridge shows a company stepping comfortably into a broader orbit while preparing to anchor operations at the new Ocean State Labs incubator in Providence in early 2026. Cambridge gives the company access. Rhode Island gives it identity. Together they form a runway instead of a split.
The investor lineup is stacked with people who know how to spot data that matters. Dolby Family Ventures led the round. Pfizer Ventures returned. Gates Frontier, Slater Technology Fund, RightHill Ventures, and the Foundation for a Better World all joined in. You do not get that roster unless your science holds weight beyond clean deck slides and polished diagrams. This is investor conviction measured in real dollars, not handshakes.
The engine behind all this momentum is MITI 101, a monoclonal antibody built to block the immune cell recruitment that drives synaptic destruction in Alzheimer’s. The team is deep in IND-enabling studies, building biomarker strategies, and preparing for Phase 1 trials supported by Wheeler Bio’s cGMP manufacturing. Every step signals a company crossing the bridge from idea to impact. This funding does more than fuel progress. It gives MindImmune Therapeutics the space to run the experiment the field has been waiting for.
Startups Startup Funding Venture Capital Series A Biotech Neurotech Neuroscience Healthcare HealthTech Infrastructure Data Data Driven Technology Innovation Tech Ecosystem Startup Ecosystem
